Limits...
Long-Term Treatment with n-3 Polyunsaturated Fatty Acids as a Monotherapy in Children with Nonalcoholic Fatty Liver Disease.

Boyraz M, Pirgon Ö, Dündar B, Çekmez F, Hatipoğlu N - J Clin Res Pediatr Endocrinol (2015)

Bottom Line: Frequency of elevated alanine aminotransferase (ALT) levels (39.2% to 14.2%; p<0.01) and elevated aspartate aminotransferase (AST) levels (25% to 17.8%; p=0.01) decreased significantly in the PUFA group.Following a 12-month diet plus placebo and lifestyle intervention treatment, 40.3% (21) of the patients in the placebo group also showed a decrease in frequency of steatosis (p=0.04) and slight decreases in frequency of elevated ALT levels (38.4% to 28.8%; p=0.01) and AST levels (30.7% to 28.8%; p>0.05).Our results indicated that n-3 PUFA treatment is safe and efficacious in obese children with NAFLD and can improve ultrasonographic findings and the elevated transaminase levels.

View Article: PubMed Central - PubMed

Affiliation: Süleyman Demirel University Faculty of Medicine, Department of Pediatric Endocrinology and Diabetes, Isparta, Turkey Phone: +90 246 211 93 02 E-mail: ozgurpirgon@gmail.com.

ABSTRACT

Objective: To investigate the efficacy and safety of n-3 polyunsaturated fatty acids (PUFA) treatment in obese children with nonalcoholic fatty liver disease (NAFLD).

Methods: One hundred and eight obese (body mass index (BMI) >95th percentile for age and sex) adolescents with NAFLD were included in the study. Mean age of the subjects was 13.8 ± 3.9 years (9-17 yrs). The diagnosis of NAFLD was based on the presence of liver steatosis with high transaminases. The subjects were randomly divided into two groups. Group 1 (PUFA group, n=52) received a 1000 mg dose of PUFA once daily for 12 months and lifestyle intervention. Group 2 (placebo group, n=56) received a recommended diet plus placebo and lifestyle intervention for 12 months. Insulin resistance was evaluated by homeostasis model assessment of insulin resistance (HOMA-IR) from fasting samples.

Results: BMI, fasting insulin levels and HOMA-IR values in both groups decreased significantly at the end of the study. In group 1, 67.8% of the patients had a decrease from baseline in the prevalence of steatosis (p<0.001). Frequency of elevated alanine aminotransferase (ALT) levels (39.2% to 14.2%; p<0.01) and elevated aspartate aminotransferase (AST) levels (25% to 17.8%; p=0.01) decreased significantly in the PUFA group. Following a 12-month diet plus placebo and lifestyle intervention treatment, 40.3% (21) of the patients in the placebo group also showed a decrease in frequency of steatosis (p=0.04) and slight decreases in frequency of elevated ALT levels (38.4% to 28.8%; p=0.01) and AST levels (30.7% to 28.8%; p>0.05).

Conclusion: Our results indicated that n-3 PUFA treatment is safe and efficacious in obese children with NAFLD and can improve ultrasonographic findings and the elevated transaminase levels.

Show MeSH

Related in: MedlinePlus

Frequency of steatosis, elevated alanine aminotransferase (ALT) and elevated aspartate aminotransferase (AST) before (black bar) and after (grey bar) the 12-month treatment in the polyunsaturated fatty acids (PUFA) group.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4563183&req=5

f3: Frequency of steatosis, elevated alanine aminotransferase (ALT) and elevated aspartate aminotransferase (AST) before (black bar) and after (grey bar) the 12-month treatment in the polyunsaturated fatty acids (PUFA) group.

Mentions: In the placebo group, 40.3% (n=21) of the patients showed a decrease from baseline in steatosis (p=0.04). The frequency of elevated serum ALT decreased from 38.4% (n=20) to 28.8% (n=15) and that of elevated serum AST from 30.7% (n=16) to 28.8% (n=15) (p=0.03; p>0.05, respectively). In the PUFA group, on the other hand, 67.8% (n=38) of patients had a decrease from baseline in the frequency of steatosis (p=0.001) and the frequency of elevated serum ALT fell from 39.2% (n=22) to 14.2% (n=8) and that of elevated serum AST from 25% (n=14) to 17.8% (n=10) (p=0.01; p=0.03, respectively) (Figures 3, 4).


Long-Term Treatment with n-3 Polyunsaturated Fatty Acids as a Monotherapy in Children with Nonalcoholic Fatty Liver Disease.

Boyraz M, Pirgon Ö, Dündar B, Çekmez F, Hatipoğlu N - J Clin Res Pediatr Endocrinol (2015)

Frequency of steatosis, elevated alanine aminotransferase (ALT) and elevated aspartate aminotransferase (AST) before (black bar) and after (grey bar) the 12-month treatment in the polyunsaturated fatty acids (PUFA) group.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4563183&req=5

f3: Frequency of steatosis, elevated alanine aminotransferase (ALT) and elevated aspartate aminotransferase (AST) before (black bar) and after (grey bar) the 12-month treatment in the polyunsaturated fatty acids (PUFA) group.
Mentions: In the placebo group, 40.3% (n=21) of the patients showed a decrease from baseline in steatosis (p=0.04). The frequency of elevated serum ALT decreased from 38.4% (n=20) to 28.8% (n=15) and that of elevated serum AST from 30.7% (n=16) to 28.8% (n=15) (p=0.03; p>0.05, respectively). In the PUFA group, on the other hand, 67.8% (n=38) of patients had a decrease from baseline in the frequency of steatosis (p=0.001) and the frequency of elevated serum ALT fell from 39.2% (n=22) to 14.2% (n=8) and that of elevated serum AST from 25% (n=14) to 17.8% (n=10) (p=0.01; p=0.03, respectively) (Figures 3, 4).

Bottom Line: Frequency of elevated alanine aminotransferase (ALT) levels (39.2% to 14.2%; p<0.01) and elevated aspartate aminotransferase (AST) levels (25% to 17.8%; p=0.01) decreased significantly in the PUFA group.Following a 12-month diet plus placebo and lifestyle intervention treatment, 40.3% (21) of the patients in the placebo group also showed a decrease in frequency of steatosis (p=0.04) and slight decreases in frequency of elevated ALT levels (38.4% to 28.8%; p=0.01) and AST levels (30.7% to 28.8%; p>0.05).Our results indicated that n-3 PUFA treatment is safe and efficacious in obese children with NAFLD and can improve ultrasonographic findings and the elevated transaminase levels.

View Article: PubMed Central - PubMed

Affiliation: Süleyman Demirel University Faculty of Medicine, Department of Pediatric Endocrinology and Diabetes, Isparta, Turkey Phone: +90 246 211 93 02 E-mail: ozgurpirgon@gmail.com.

ABSTRACT

Objective: To investigate the efficacy and safety of n-3 polyunsaturated fatty acids (PUFA) treatment in obese children with nonalcoholic fatty liver disease (NAFLD).

Methods: One hundred and eight obese (body mass index (BMI) >95th percentile for age and sex) adolescents with NAFLD were included in the study. Mean age of the subjects was 13.8 ± 3.9 years (9-17 yrs). The diagnosis of NAFLD was based on the presence of liver steatosis with high transaminases. The subjects were randomly divided into two groups. Group 1 (PUFA group, n=52) received a 1000 mg dose of PUFA once daily for 12 months and lifestyle intervention. Group 2 (placebo group, n=56) received a recommended diet plus placebo and lifestyle intervention for 12 months. Insulin resistance was evaluated by homeostasis model assessment of insulin resistance (HOMA-IR) from fasting samples.

Results: BMI, fasting insulin levels and HOMA-IR values in both groups decreased significantly at the end of the study. In group 1, 67.8% of the patients had a decrease from baseline in the prevalence of steatosis (p<0.001). Frequency of elevated alanine aminotransferase (ALT) levels (39.2% to 14.2%; p<0.01) and elevated aspartate aminotransferase (AST) levels (25% to 17.8%; p=0.01) decreased significantly in the PUFA group. Following a 12-month diet plus placebo and lifestyle intervention treatment, 40.3% (21) of the patients in the placebo group also showed a decrease in frequency of steatosis (p=0.04) and slight decreases in frequency of elevated ALT levels (38.4% to 28.8%; p=0.01) and AST levels (30.7% to 28.8%; p>0.05).

Conclusion: Our results indicated that n-3 PUFA treatment is safe and efficacious in obese children with NAFLD and can improve ultrasonographic findings and the elevated transaminase levels.

Show MeSH
Related in: MedlinePlus